{"id":"nct:NCT07570654","kind":"trial","title":"Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder","authors":["COMPASS Pathways"],"author_count":1,"year":2026,"published":"2026-05-06","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT07570654","source_url":"https://clinicaltrials.gov/study/NCT07570654","archive_url":"https://space-kitty.com/papers/nct:NCT07570654","updated":"2026-10-23","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"The Redefine Study (COMP202) is testing COMP360 to see if it may reduce post-traumatic stress disorder (PTSD) symptoms when administered alongside monitoring and support from a trained study team. COMP360 is a lab-made form of the naturally occurring chemical compound psilocybin.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["PTSD - Post Traumatic Stress Disorder","PTSD","PTSD Symptoms","PTSD, Post Traumatic Stress Disorder"],"details":{"acronym":"Redefine","status":"RECRUITING","phase":"PHASE2, PHASE3","study_type":"INTERVENTIONAL","enrollment":300,"sponsor":"COMPASS Pathways","conditions":["PTSD - Post Traumatic Stress Disorder","PTSD","PTSD Symptoms","PTSD, Post Traumatic Stress Disorder"],"interventions":["DRUG: COMP360 psilocybin"],"start_date":"2026-09-01","start_date_type":"ESTIMATED","primary_completion_date":"2028-11-01","has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"psychiatric-therapeutics","name":"Novel Psychiatric Therapeutics","domain_slug":"neuroscience"}],"cited_in_dossiers":[]}